BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September

Day

• 1
• 2
• 3
• 4

• Press Releases

  Fresenius Kabi Launches Generic Sugammadex in Simplist® Ready‑to‑Administer Prefilled Syringe in the U.S.

  September 3, 2026

   · 

  6 min read
• Press Releases

  Nextleaf Solutions Reports Fiscal Q3 2026 Financial Results

  September 3, 2026

   · 

  6 min read
• Press Releases

  Veradermics to Present at Upcoming September 2026 Investor Conferences

  September 3, 2026

   · 

  2 min read
• 

  Approvals

  FDA approves Ionis’ antisense drug as first targeted therapy for Alexander disease

  Zanvastro, an antisense oligonucleotide therapy, represents the first independent neurology launch for Ionis Pharmaceuticals, which intends to leverage the foothold for more approvals in rare neurodegenerative diseases, including Angelman syndrome.

  September 3, 2026

   · 

  5 min read

   · 

  Heather McKenzie
• Press Releases

  eGenesis Announces Clinical Update in Ongoing Expanded Access Study of EGEN-2784 in Patients with Kidney Failure

  September 3, 2026

   · 

  4 min read
• Press Releases

  Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

  September 3, 2026

   · 

  20 min read
• Press Releases

  ZANVASTRO™ (zilganersen) approved by the FDA as the first and only disease modifying treatment for Alexander disease (AxD) in pediatric and adult patients

  September 3, 2026

   · 

  12 min read